1,018 results match your criteria Lupus Erythematosus Subacute Cutaneous


CAN SKIN BE A MARKER FOR INTERNAL MALIGNANCY? EVIDENCE FROM CLINICAL CASES.

Acta Clin Croat 2021 Dec;60(4):711-721

1Department of Dermatovenereology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 3Unit of Dermatology and Venereology, Zabok General Hospital, Bračak/Zabok, Croatia; 4Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 5Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Although there are many single case reports on paraneoplastic dermatoses in the literature, there are very rare articles containing multiple cases. A retrospective study was performed to examine paraneoplastic dermatoses and accompanying malignancies based on skin manifestations and appropriate diagnostic evaluations. We recorded outcomes, current conditions, and surgical/oncologic treatments. Read More

View Article and Full-Text PDF
December 2021

Nivolumab-Induced de novo Discoid Lupus Erythematosus.

Case Rep Dermatol 2022 Jan-Apr;14(1):88-92. Epub 2022 Apr 21.

Department of Dermatology, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.

An increasing number of checkpoint inhibitor-induced subacute cutaneous lupus erythematosus events have been reported. We present the first case of nivolumab-induced discoid lupus erythematosus in a patient with hepatocellular carcinoma. The patient presents with violaceous hypopigmented plaques on the pinna bilaterally, hypopigmented plaques with central hyperpigmentation on the posterior neck, and other hypopigmented plaques on the face, forearms, and hands. Read More

View Article and Full-Text PDF

Proton pump inhibitor induced subacute cutaneous lupus erythematosus: Clinical characteristics and outcomes.

Lupus 2022 May 30:9612033221104237. Epub 2022 May 30.

Louise Coote Lupus Unit, 111988Guy's Hospital, London, UK.

Background: There is a growing literature reporting the association between proton pump inhibitor (PPI) use and subacute cutaneous lupus erythematosus (SCLE).

Aims: To compare the clinical characteristics of a cohort of patients with PPI-induced SCLE, their clinical course and treatment with a control group of primary SCLE patients not exposed to PPI.

Methods: We conducted a matched case-control study in a tertiary referral setting at the Louise Coote Lupus Unit. Read More

View Article and Full-Text PDF

Subacute cutaneous lupus erythematosus following ChAdOx1 nCoV-19 vaccination.

J Dermatol 2022 May 27. Epub 2022 May 27.

Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

View Article and Full-Text PDF

B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus.

BMJ Case Rep 2022 May 27;15(5). Epub 2022 May 27.

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India

A woman in her 20s presented with chilblains for 2 years and recent-onset photodistributed psoriasiform plaques. She did not have persistent good improvement despite treatment with 1 mg/kg oral prednisolone, along with successive trials with many steroid-sparing adjuvants in adequate dosage and duration, including hydroxychloroquine, methotrexate and cyclosporine, in the following 6 months. The patient had an excellent improvement and went into remission with two doses of injection rituximab, 1 g each, at a 2-week interval. Read More

View Article and Full-Text PDF

Prominent B cell signature differentiates discoid from subacute cutaneous lupus erythematosus.

J Invest Dermatol 2022 May 17. Epub 2022 May 17.

Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA; Department of Medicine, Division of Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address:

While B cells account for a significant proportion of the lymphocytic infiltrate in discoid lupus erythematosus (DLE), their contribution to pathogenesis is unknown. In this study, we compare the immune landscape of 17 subjects with DLE to 21 subjects with subacute cutaneous lupus erythematosus (SCLE) using transcriptomic and histologic analyses of lesional skin. A few of the subjects (3/17 DLE, 5/21 SCLE) had concomitant systemic lupus erythematosus (SLE). Read More

View Article and Full-Text PDF

Amlodipine-Induced Subacute Cutaneous Lupus Erythematosus Localized to Non-Sun-Exposed Areas.

Case Rep Dermatol 2022 Jan-Apr;14(1):71-76. Epub 2022 Mar 29.

Department of Dermatology, Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Tokyo, Japan.

The cutaneous manifestations of subacute cutaneous lupus erythematosus (SCLE), a subset of cutaneous lupus erythematosus, arise most often in sun-exposed areas. We report a case of SCLE with atypical distribution, following treatment with amlodipine. This highlighted a possible clue that can be used to clinically distinguish a drug-induced case from an idiopathic disorder. Read More

View Article and Full-Text PDF

Papulonodular Mucinosis Associated With Subacute Lupus.

Cureus 2022 Mar 23;14(3):e23412. Epub 2022 Mar 23.

Department of Dermatology, Ibn Rochd University Hospital, Casablanca, MAR.

Papulonodular mucinosis is a rare but well-documented finding associated with systemic and cutaneous forms of lupus erythematosus (LE). It occurs exceptionally in association with subacute cutaneous lupus erythematosus (SCLE). Its etiology and pathogenesis remain to be elucidated. Read More

View Article and Full-Text PDF

Positive Antinuclear Antibody (ANA)-Negative Systemic Lupus Erythematosus (SLE) Presenting With Acute Pancreatitis.

Cureus 2022 Mar 10;14(3):e23031. Epub 2022 Mar 10.

Cardiology, Nilratan Sircar Medical College, Kolkata, IND.

Systemic lupus erythematosus (SLE) is an autoimmune disease with multisystem involvement and most commonly affects women of childbearing age. Most of the patients, if not all, have positive antinuclear antibody (ANA) in their serum. ANA-negative SLE is extremely rare. Read More

View Article and Full-Text PDF

Lupus erythematosus: Management of cutaneous manifestations during pregnancy.

Dermatol Ther 2022 Jun 29;35(6):e15486. Epub 2022 Apr 29.

Dermatology and Venereology Department, North Lisbon University Hospital Center, Lisbon, Portugal.

Lupus erythematosus is an autoimmune disease that often affects the skin. Cutaneous manifestations are generally subdivided into different subtypes, including acute, subacute, and chronic courses. Management of lupus erythematosus cutaneous manifestations during pregnancy remains a clinical challenge until nowadays. Read More

View Article and Full-Text PDF

Toxic Epidermal Necrolysis-Like Lupus Erythematous Presentation Following SARS-CoV-2 Infection.

J Med Cases 2022 Feb 16;13(2):89-93. Epub 2022 Feb 16.

Internal Medicine Department, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra 3004-561, Portugal.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Infectious agents have been implicated in the pathogenesis of SLE. The emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a pro-inflammatory cytokine storm and has been linked to autoimmune phenomena, which can lead to the onset of autoimmune diseases. Read More

View Article and Full-Text PDF
February 2022

Clinicohistological and immunopathological features of patients with cutaneous lupus erythematosus at tertiary dermatology centre in Malaysia.

Clin Exp Dermatol 2022 Mar 22. Epub 2022 Mar 22.

Department of Dermatology, Hospital Pulau Pinang, Penang, Malaysia.

Background: Cutaneous lupus erythematosus (CLE) is a chronic, autoimmune skin disease with a wide spectrum of clinical presentations in different populations.

Aim: To study the clinicohistological and immunological features of CLE in a multiethnic population and to identify the predictive factors of disease severity based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).

Methods: This was a cross-sectional study of CLE conducted from March 2019 to February 2020. Read More

View Article and Full-Text PDF

Paraneoplastic subacute cutaneous lupus erythematosus with mucositis.

JAAD Case Rep 2022 Apr 17;22:38-41. Epub 2022 Feb 17.

Department of Dermatology, University of Utah, Salt Lake City, Utah.

View Article and Full-Text PDF

Skin CD4 Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases.

J Autoimmun 2022 04 9;128:102811. Epub 2022 Mar 9.

Department of Dermatology, The Second Xiangya Hospital of Central South University; Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, 410011, China; Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, 210042, China; Key Laboratory of Basic and Translational Research on Immune-Mediated Skin Diseases, Chinese Academy of Medical Sciences, Nanjing, China; Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Nanjing, China. Electronic address:

Background: Although the contribution of aberrant CD4 T cell signaling to systemic lupus erythematosus (SLE) is well established, its role in cutaneous lupus erythematosus (CLE) skin is largely unknown. Because the rate of systemic manifestations varies in each subtype, resident memory CD4 T cells in lesions that are responsible for only skin-associated tissue responses may vary in each subtype. However, the role of CD4 tissue-resident memory T (CD4 Trm) cells in each CLE subtype remains unclear. Read More

View Article and Full-Text PDF

Annular scaly plaques with peripheral pustules.

JAAD Case Rep 2022 Mar 21;21:185-188. Epub 2022 Jan 21.

Department of Dermatology, Bay Pines Veterans Affairs Healthcare System, Bay Pines, Florida.

View Article and Full-Text PDF

Case Report: Rowell Syndrome-Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection.

Front Med (Lausanne) 2022 14;9:815743. Epub 2022 Feb 14.

Department of Dermatology and Venereology, Medical University-Sofia, Sofia, Bulgaria.

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an important impact on dermatology practice, posing diagnostic and therapeutic challenges especially in patients with inflammatory and autoimmune skin disorders. Disease-specific and nonspecific cutaneous manifestations have been increasingly reported in the spectrum of COVID-19 but the influence of the infection on pre-existing dermatologic diseases has not been clearly defined. There has been a debate in the literature as to whether patients suffering from autoimmune dermatoses, including cutaneous lupus erythematosus (CLE), are at increased risk of SARS-CoV-2 infection, as well as if they experience worsening of their lupus erythematosus (LE)-related clinical symptoms. Read More

View Article and Full-Text PDF
February 2022

Subacute Cutaneous Lupus as a Paraneoplastic Manifestation of Non-Hodgkin Lymphoma.

J Investig Med High Impact Case Rep 2022 Jan-Dec;10:23247096211063066

The University of Toledo, OH, USA.

Malignancies have been associated with paraneoplastic syndromes, such as dermatomyositis. Subacute cutaneous lupus erythematosus (SCLE) can occur due to a wide array of cancers. Paraneoplastic SCLE obeys McLean's criteria and often regresses after the underlying malignancy has been treated appropriately. Read More

View Article and Full-Text PDF

A case of belatacept-induced chilblain lupus.

JAAD Case Rep 2022 Mar 22;21:112-115. Epub 2022 Jan 22.

Department of Dermatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.

View Article and Full-Text PDF

Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: A Case Series of 7 Patients and Brief Review of Literature.

Indian Dermatol Online J 2022 Jan-Feb;13(1):64-72. Epub 2022 Jan 24.

Department of Pathology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Background: Subacute cutaneous lupus erythematosus (SCLE) manifests with erythematous, nonscarring, annular, or papulosquamous plaques. Proton pump inhibitors (PPIs) are increasingly being incriminated in its causation, but reports of similar nature from India are lacking.

Aims: To describe the characteristics of seven patients with SCLE induced by PPIs and to review the published cases in order to provide a better perspective of the association. Read More

View Article and Full-Text PDF
January 2022

Colocalisation of subacute cutaneous lupus erythematosus and vitiligo in a woman with thyroid autoantibodies: An intriguing association.

Indian J Dermatol Venereol Leprol 2022 Mar-Apr;88(2):219-221

Department of Dermatology, Venereology and Leprosy, Vijayanagara Institute of Medical Sciences, Ballari, Karnataka, India.

View Article and Full-Text PDF

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review.

Clin Cosmet Investig Dermatol 2022 13;15:51-62. Epub 2022 Jan 13.

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Reports of immune-related adverse events caused by programmed cell death-ligand 1 (PD-L1) inhibitor have been emerging. Herein, we report a subacute cutaneous lupus erythematosus (SCLE)-like eruption presented after the treatment of durvalumab in a patient with extensive-stage small cell lung carcinoma. A 74-year-old Thai man was referred to our department after experiencing multiple dusky red to brownish papules and patches with scale and erosions on photo-distributed areas after receiving 3 infusion cycles of durvalumab. Read More

View Article and Full-Text PDF
January 2022

Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.

Authors:
Edward K L Chan

Clin Rev Allergy Immunol 2022 Jan 18. Epub 2022 Jan 18.

Department of Oral Biology, University of Florida, 1395 Center Drive, Gainesville, FL, 32610-0424, USA.

This review highlights the 30 plus years research progress since the discovery of autoantibody to Ro52/TRIM21 in patients with systemic lupus erythematosus (SLE) and Sjögren's syndrome (SjS). After the initial expression cloning of the Ro52 cDNA, it has taken many years to the current understanding in the interesting biological function of Ro52 as an E3 ubiquitin ligase and its role in innate immune clearance of intracellular IgG-bound complex. Early observations show that anti-Ro52, mostly associated with anti-SS-A/Ro60 and/or anti-SS-B/La, is commonly found in SLE (40-70%), SjS (70-90%), neonatal lupus erythematosus (NLE, 75-90%), and subacute cutaneous lupus erythematosus (50-60%). Read More

View Article and Full-Text PDF
January 2022

Dermatological adverse effects of anti-glaucoma eye drops: a review.

J Eur Acad Dermatol Venereol 2022 May 11;36(5):661-670. Epub 2022 Feb 11.

Service de Dermatologie, CHRU DE NANCY Brabois, Bâtiment des Spécialités Médicales, Vandœuvre lès Nancy, France.

Many patients are treated for glaucoma. Like other drugs, anti-glaucoma eye drops may induce dermatological adverse effects. We aim to review the dermatological adverse effects secondary to the active agents in anti-glaucoma eye drops through a literature review. Read More

View Article and Full-Text PDF

Radiation-induced subacute cutaneous lupus erythematosus.

Clin Exp Dermatol 2022 Jun 14;47(6):1184-1185. Epub 2022 Mar 14.

Department of Dermatology, Kingston Hospital, Kingston upon Thames, UK.

We present an unusual case of radiation-induced subacute cutaneous lupus erythematosus (SCLE) occurring in a patient with non-Hodgkin lymphoma. Dermatologists should be aware of the ability of low-dose radiation treatment to induce a first presentation or flare of SCLE, with the possibility of extension of disease outside of the radiation field. Read More

View Article and Full-Text PDF

Annular lichenoid diseases.

Clin Dermatol 2021 Dec 31. Epub 2021 Dec 31.

Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida, USA.

Annular lichenoid diseases encompass a diverse range of pathologies that present as circular, raised, or flat lesions that may vary in size and number. Examples include annular lichenoid dermatitis of youth, annular lichen planus, erythema dyschromicum perstans, erythema multiforme, fixed drug eruption, lichen sclerosus, neonatal lupus, porokeratosis, subacute cutaneous lupus erythematosus, and lichenoid syphilis. Clinical morphology and histopathology can differentiate these entities. Read More

View Article and Full-Text PDF
December 2021

B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.

Front Immunol 2021 19;12:775353. Epub 2021 Nov 19.

Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.

Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease characterized by a diverse cadre of clinical presentations. CLE commonly occurs in patients with systemic lupus erythematosus (SLE), and CLE can also develop in the absence of systemic disease. Although CLE is a complex and heterogeneous disease, several studies have identified common signaling pathways, including those of type I interferons (IFNs), that play a key role in driving cutaneous inflammation across all CLE subsets. Read More

View Article and Full-Text PDF
February 2022

Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia.

Clin Exp Dermatol 2022 Apr 18;47(4):787-788. Epub 2022 Jan 18.

Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth, Hospital Oberhausen, University Witten-Herdecke, Oberhausen, Germany.

We read with great interest the recently published article by Joos et al. on the successful use of baricitinib for cutaneous lupus erythematosus. The authors presented a heavily pretreated case of subacute cutaneous lupus erythematosus (SCLE) with almost complete clearance following 6 months of baricitinib therapy. Read More

View Article and Full-Text PDF

Subacute cutaneous lupus erythematosus induction after SARS-CoV-2 vaccine in a patient with primary biliary cholangitis.

J Eur Acad Dermatol Venereol 2022 Mar 2;36(3):e179-e180. Epub 2021 Dec 2.

Dermatology Unit, IRCCS of Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

View Article and Full-Text PDF

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib.

Clin Exp Dermatol 2022 Apr 13;47(4):748-750. Epub 2021 Dec 13.

Division of Rheumatology, Kantonsspital St Gallen, St Gallen, Switzerland.

We report on a patient who presented with refractory subacute cutaneous lupus erythematosus. The scaly annular and polycyclic patches/plaques, and hyperkeratotic lesions on multiple fingers improved rapidly after treatment with baricitinib. Read More

View Article and Full-Text PDF

Low disease activity state in juvenile-onset systemic lupus erythematosus.

Lupus 2021 Nov 1;30(13):2144-2150. Epub 2021 Nov 1.

Department of Pediatric Rheumatology, University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey.

Objectives: To determine the rate of achieving The Lupus Low Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE) for tracing pertinent treatment modalities.

Methods: A total of 122 juvenile-onset SLE (jSLE) patients from six pediatric rheumatology centers in Turkey were enrolled in the study. LLDAS-50 was defined as encountering LLDAS for at least 50% of the observation time. Read More

View Article and Full-Text PDF
November 2021